Grant: Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
University of Toronto
$25,000.00
Assessing the role and preventative or therapeutic effects of Faecalibacterium prausnitzii and other candidate bacteria in non-alcoholic fatty liver disease
EF 2018-19
Résumé
Non-alcoholic fatty liver disease (NAFLD) is a public health issue associated with obesity, insulin resistance (IR) or metabolic syndrome (MSx). Its economic burden on healthcare is high as it can progress to liver failure requiring transplantation. It often recurs post-transplant affecting long-term survival.Treatment like diet, weight loss and exercise have limited success. Manipulation of the gut bacteria may be one strategy to prevent or treat this disease. Certain types of bacteria (eg. F. prausnitzii) may have beneficial effects by reducing inflammation, leaky gut and bacterial toxins in the blood that can contribute to NAFLD. We will leverage previous CIHR grants into an ambitious study by answering the following: 1) Does fecal microbiota transplant (FMT) from NAFLD patients trigger the same disease in germ-free mice fed special diets. 2) Can increasing good bacteria (eg. F. prausnitzii) reverse NAFLD? 3) Can prebiotics increase good bacteria and prevent NAFLD? Certain fibers or prebiotics increase good bacteria reducing leaky gut and bacterial toxins in the blood. This can improve NAFLD. Mice on diets inducing NAFLD will receive prebiotics and we will assess if it prevent or treat NAFLD. Through these experiments (1-3), we will assess leaky gut; liver histology, fat and immune cells; body fat composition; IR; bile acids; bacterial composition and metabolites and; liver gene expression. 4) Finally, in pilot studies, we will determine if candidate pre- or probiotics identified in our previous experiments will improve NAFLD in humans, first in post-liver transplant recipients (prebiotic) and secondly, in non-transplant patients with NAFLD (probiotic). We will assess liver fat by imaging (magnetic resonance), liver biomarkers, IR, and bacterial composition and metabolites. Prebiotic will be use in transplant due to immunosuppression. These studies aim to identify and increase the abundance of good bacteria to prevent or treat NAFLD and improve IR.
Programme
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
398980
Name
Allard Johane P
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Team Grant : Canadian Microbiome Initiative 2: Research Teams
Projecttitle
Assessing the role and preventative or therapeutic effects of Faecalibacterium prausnitzii and other candidate bacteria in non-alcoholic fatty liver disease
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Keyworddelim
Fecal Microbiota Transplant; Human; Intestinal Microbiome; Liver Transplant; Metabolic Syndrome; Mice; Non-Alcoholic Fatty Liver Disease; Nutrition; Prebiotics; Probiotics
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a public health issue associated with obesity, insulin resistance (IR) or metabolic syndrome (MSx). Its economic burden on healthcare is high as it can progress to liver failure requiring transplantation. It often recurs post-transplant affecting long-term survival.Treatment like diet, weight loss and exercise have limited success. Manipulation of the gut bacteria may be one strategy to prevent or treat this disease. Certain types of bacteria (eg. F. prausnitzii) may have beneficial effects by reducing inflammation, leaky gut and bacterial toxins in the blood that can contribute to NAFLD. We will leverage previous CIHR grants into an ambitious study by answering the following: 1) Does fecal microbiota transplant (FMT) from NAFLD patients trigger the same disease in germ-free mice fed special diets. 2) Can increasing good bacteria (eg. F. prausnitzii) reverse NAFLD? 3) Can prebiotics increase good bacteria and prevent NAFLD? Certain fibers or prebiotics increase good bacteria reducing leaky gut and bacterial toxins in the blood. This can improve NAFLD. Mice on diets inducing NAFLD will receive prebiotics and we will assess if it prevent or treat NAFLD. Through these experiments (1-3), we will assess leaky gut; liver histology, fat and immune cells; body fat composition; IR; bile acids; bacterial composition and metabolites and; liver gene expression. 4) Finally, in pilot studies, we will determine if candidate pre- or probiotics identified in our previous experiments will improve NAFLD in humans, first in post-liver transplant recipients (prebiotic) and secondly, in non-transplant patients with NAFLD (probiotic). We will assess liver fat by imaging (magnetic resonance), liver biomarkers, IR, and bacterial composition and metabolites. Prebiotic will be use in transplant due to immunosuppression. These studies aim to identify and increase the abundance of good bacteria to prevent or treat NAFLD and improve IR.
Competitiondate
201811
Approvedterm2
1 yr 0 mth
Pinamesdelim
Allard, Johane P; Bhat, Mamatha; Gaisano, Herbert Y; Hota, Susy S; Philpott, Dana J; Poutanen, Susan M
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $25,000~ $0~